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Acute Graft-Versus-Host Disease: Grade and Outcome in Patients With 
Chronic Myelogenous Leukemia
By A. Gratwohl, J. Hermans, J . Apperley, W. Arcese, A. Bacigalupo, G. Bandirli, P. di Bartolomeo, M. Boogaerts,
A. Bosi, E. Carreras, A. Devergie, A. Ferrant, W.E. Fibbe, F. Frassoni, G. Gahrton, J. Goldman, A. Iriondo,
N. Jacobsen, H J. Kolb, H. Link, M. Michallet, H.G. Prentice, J. Reiffers, F.v. Rhee, T. Ruutu, H. Schwaighofer, 
J.P. Vernant, T. de Witte, and D. Niederwieser for the Working Party Chronic Leukemia of the European Group
for Blood and Marrow Transplantation
Acute graft-versus-host disease (aGVHD) has been classified 
according to the Seattle criteria as grades 0, I, II, III, and IV 
for 20 years. The predictive value of such detailed grading 
is a matter of debate; publications usually report GVHD as 
present or absent or as absent, moderate, or severe. The 
Working Party Chronic Leukemia of the European Group for 
Bone Marrow Transplantation analyzed data of 1,294 pa­
tients transplanted from an allogeneic donor for chronic my­
elogenous leukemia (CML) in first chronic phase and tested 
the predictive value of aGVHD grading for the following end­
points: day 100 mortality (D100M), transplant-related mor­
tality (TRM), relapse incidence (Rl), leukemia-free survival 
(LFS), and survival (SURV). aGVHD was absent in 462 pa­
tients (35.7%), grade I occurred in 335 (25.8%), grade II in 
264 (20.5%), grade III in 110 (8.5%), and grade IV in 123 pa­
tients (9.5%). A total of 297 patients (23%) died within 100 
days, 495 patients (38%) died of any TRM, and 100 patients
(8%) died of relapse. D100M according to grades 0, I, II, III, 
and IV was 17%, 13%, 19%, 38%, and 70%, respectively, with 
significant difference between 0-II versus lll-IV. TRM was 
28%, 27%, 43%, 68%, and 92%, respectively, with a distinct 
separation between 0-I versus ll-IV. Rl showed a continuous 
decrease of 37%, 30%, 23%, 18%, and 8%, respectively, with 
increasing aGVHD. LFS was 45%, 51%, 44%, 26%, and 7%, 
respectively, and was best for patients with grade I aGVHD. 
This finding was also reflected in a better overall survival 
(60%, 64%, 53%, 30%, and 8%, respectively). The better LFS  
for grade I aGVHD patients compared with patients with 
grade 0 or II aGVHD was confirmed (P — .05) in a multivariate 
analysis. These data document the value of the present 5- 
point grading of aGVHD, ie, different outcome is observed 
depending on endpoint analyzed. Restricting information 
about aGVHD to presence or absence is not warranted.
© 1995 by The American Society of Hematology.
GRAFT-VERSUS-HOST disease (GVHD) remains a major complication o f allogeneic bone marrow trans­
plantation (BMT) and a significant determinant for out­
come.'-6 Acute GVHD (aGVHD) is traditionally classified 
according to the Seattle criteria in a 5-point clinical staging 
system according to the three main organs involved: skin, 
gastrointestinal tract, and liver.1 Based on these organ scores, 
an overall clinical grading was defined from 0 to IV. The 
value of such a finely tuned classification system as a pre­
dictive tool has never been analyzed in detail. In some analy­
ses, patients with overall grades 0 and I are considered as 
“ aGVHD absent” and patients with grades II, III, and IV 
as “ aGVHD present.” Alternatively, aGVHD is reported as 
absent (grade 0), mild or moderate (grades I and II), or severe 
(grades III and IV).
Using a large cohort o f patients treated with allogeneic 
BMT for one indication, chronic myelogenous 
(CML) in first chronic phase, we examined the influence and 
prognostic value o f this 5-point overall grading system of  
aGVHD. Our study was initiated by a workshop held at a 
UCLA conference on bone marrow transplantation (January 
1994, Keystone, CO) and intended as a review of the 25 
years of experience with the Seattle criteria that addressed 
the prognostic value of the 5-point grading on the following 
endpoints: day 100 mortality (D100M), transplant-related 
mortality (TRM), relapse incidence (Rl), leukemia-free sur­
vival (LFS), and overall survival (SURV). In addition, the 
conventional 5-point scale was compared with a dichoto­
mised system using absence or presence of GVHD and a 
system using absent, moderate, or severe as grading.
PATIENTS AND METHODS
Study design and data collection. The present analysis is a retro­
spective study based tin data collected by the EBMT between 1979 
and 1990.
The data were collected by questionnaire containing information 
on donor and recipient identity, sex, age, and histocompatibility. 
Moreover, patient data were available on primary disease, transplant 
procedure, conditioning, GVHD prevention method, and outcome. 
The data were collected annually and updated as of January 1, 1993, 
For logistic reasons, not all teams reported all their patients. Some 
teams ceased to report, whereas some only began reporting at a later 
stage. The participating institutions are listed in the Appendix.
Patients. The present analysis concentrates on 1,294 
with CML transplanted in first chronic phase of their disease with 
bone marrow from an allogeneic donor. Identical twin transplants 
and patients with second transplants were excluded.
Table 1 summarizes the patient and transplant characteristics in 
regard to age, donor recipient sex combination, GVHD prevention 
method, donor source, year of transplant, and interval from diagnosis 
to transplant. Of the 1,294 patients with CML, 58% were male 
and 42% were female. Male patients receiving female bone marrow 
represent 330 cases (26%). The median age was 33 years, with a
range from 0.5 to 58 years. One -two patients )
were 20 years or younger and 1,142 patients were older than 20 
years. The donor was an HLA-identical sibling in 90% of the patients 
(n -  1,160) and a nonidentical related or unrelated donor in 10% 
(n = 134). For 30% of all patients (n = 385), donor marrow was 
T-cell depleted as method of GVHD prevention. Fifty-five percent 
of transplants were performed before 1988 and 45% between I98K
and 1990. The interval from diagnosis to transplant was ssl year in
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Table 1. Incidence and Severity of aGVHD Depending on Age, Sex, T-Cell Depletion, Donor Source, Year of Transplant, and Interval From




Grade of aGVHD (%)
Probability of Significant 
Differences Between 
Categories (P)





Total 1,294 (100) 35.7 25.8 20.5 8.5 9.5
Age of patient (yr) .1* . I t
^ 2 0 152 (12) 42 25 17 5 11
> 2 0 1,142 (88) 35 26 21 9 9
Donor recipient sex combination ,62* .58t
Female donor/male recipient 330 (26) 37 22 20 9 12
Other 964 (74) 35 27 21 9 9
GVHD prevention method <.001* <.001 +
No T-cell depletion 909 (70) 29 26 23 10 12
T-cell depletion 385 (30) 51 26 14 6 4
Donor source .009* .002+
HLA-identical sibling 1,160 (90) 37 26 20 8 9
Nonidentical related donor 44 (3) 32 32 11 2 23
Unrelated donor 90 (7) 21 26 26 14 13
Year of BMT
=£1987 718 (55) 38 23 20 8 11 .03* .48t
^1988 576 (45) 32 30 21 9 8
Interval between diagnosis and therapy (mo)
0-12 592 (47) 39 28 18 7 7
13-24 352 (28) 28 26 24 9 13 .004* <,001*
> 2 4 328 (26) 35 23 22 10 10
* x 2 test.
t  Mann-Whitney test. 
£ Kruskall-Wallis test.
47%, between 1 and 2 years in 27%, and more than 2 years in 26% 
of the patients.
Grading o f  aGVHD and endpoints. The participating teams were 
asked to enter the grade of aGVHD according to the Seattle criteria.1 
To investigate the inlluenee of the aGVHD grade, we looked at 
several endpoints: D100M, TRM, RI, LFS, and SURV. The criteria 
defining these endpoints have been published.7 For relapse, clinical 
relapse has been taken as endpoint.
Statistical analysis. Discrete variables in cross-tables and inci­
dence of aGVHD (grade 0 v 1 + II + III + IV) in Table 1 was 
analyzed with the x '  lest. Severity was compared for the different 
categories of age, sex, GVHD prevention method, and year of BMT 
by the nonparametric Mann-Whitney test and for the donor source 
and interval from diagnosis to transplant by the Kruskall-Wallis test. 
The inlluenee of different grades of aGVHD on DIOOM was ana­
lyzed with a logistic regression.7 For each of the grades I or higher, 
relative risks with respect to grade 0 were assessed. Adjustments 
are made for the covariables sex match, age, donor source, T-eell 
depletion, year of BMT, and interval from diagnosis to transplant, 
as listed in Table 1. Similar analyses were performed for the other 
endpoints using Cox regression. To assess the influence of moderate 
aGVHD on relapse and LFS, the same analyses were repeated but 
restricted to the 1,061 patients with grade 0 , 1, or II aGVHD. Relapse 
incidence was also compared in a trend analysis.
All analyses were performed with the SPSS computer program 
(SPSS Inc, Chicago, IL).
RESULTS
Follow-up and endpoints. At the time of analysis, 699 
of 1,294 patients (54%) were alive, 563 (44%) were aiive
without relapse at time of last follow-up, and 595 had died 
(46%). Median follow-up of living patients was 52 months.
Two hundred ninety patients (23%) died within 100 days 
of transplant; 15 patients were censored within 100 days. A 
total of 495 patients (38%) died of TRM and 236 patients 
(18%) relapsed, 100 (8%) of whom died.
Incidence and severity o f  aGVHD. Although 462 pa­
tients (36%) never had any signs of aGVHD, 832 patients 
(64%) showed grades I to IV; 497 (38%) had grade II or 
higher aGVI-ID. The individual grades are listed according 
to age, sex, GVI-ID prevention method, donor source, and 
year of BMT (Table 1). Incidence and severity were similar 
in the two sex-matched categories and two age classes. There 
were large and significant differences in incidence and sever­
ity of the aGVHD grades for GVI-ID prevention and donor 
source. Patients with T-cell-depleted bone marrow had less 
GVHD and patients with donors other than HLA-identical 
siblings had more frequent and more severe aGVHD. There 
was no difference in severity of GVI-ID in the two time 
cohorts, but a slightly larger number o f patients transplanted 
before 1988 had no GVHD. This coincides with the time 
period of more T-cell depletion.
Influence o f  acute GVHD on D100M, TRM, RI, LFS, and 
SURV. The presence and severity of aGVI-ID have a strong 
impact on D100M, TRM, RI, LFS, and SURV (Fig 1 and 
Table 2). Patients with no GVHD have lower D100M and 
TRM but higher RI than do patients with GVHD. There is 
an increase in D100M and TRM with increasing aGVHD
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Fig 1. Analysis of outcome in 1,294 patients 
transplanted for CML in first chronic phase. Percent­
age of patients dying within 100 days (D100M) and 5 
years' probability of patients dying of any transplant 
related mortality (TRM), dying of relapse (relapse), 
alive (SURV), and being well without leukemia (LFS) 
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and a decrease in RI, SURV, and LFS are better for patients 
with grade I aGVHD than for those with grade 0. From 
grade I onwards up to grade IV, they are continuously de­
creasing. This observation is true for patients below or above 
20 years of age, independent of T-cell depletion and trans­
plant source, ie, HLA-identical sibling, nonidentical family 
member or unrelated donor. The same pattern is observed 
in transplants before or after 1988 and independent of the 
time interval from diagnosis to transplant.
However, there is a different pattern for each endpoint 
investigated in the present analysis (Fig 1). D100M increases 
significantly from grade III onwards; TRM increases already 
from grade II GVHD. In contrast, RI decreases gradually 
with each grade. Because of this discordant effect of TRM 
and RI, LFS and SURV are best for patients with grade I 
aGVHD. These findings were consistent for all patients or 
when patients were analyzed separately in subgroups for age, 
sex, or donor type. Therefore, data for all patients were 
analyzed together. Table 3 gives the quantitative analysis of 
the influence of aGVHD grade by logistic regression with
Table 2. Influence of aGVHD Score on Outcome for 1,294 Patients 
With CML (1,160 HLA-id Sibling BMT) After Allogeneic BMT
in First Chronic Phase
aGVHD Score N D100M* SURV+ TRMt Rlt LFSt
0 462 17% 60% 28% 37% 45%
(429) (15%) (62%) (27%) (37%) (46%)
I 335 13% 64% 27% 30% 51%
(298) (11%) (65%) (25%) (31%) (52%)
II 264 19% 53% 43% 23% 44%
(236) (17%) (56%) (40%) (24%) (46%)
III 110 38% 30% 68% 18% 26%
(96) (35%) (31%) (67%) (14%) (28%)
IV 123 70% 8% 92% 8% 7%
(101) (71%) (9%) (91%) (9%) (8%)
Total 1,294 23% 52% 41% 31% 41%
(1,160) (21%) (54%) (38%) (31%) (41%)
* Incidence.
t Probability at 5 years.
adjustment for the covariables age, sex, GVHD prevention, 
donor type, year of BMT, and interval from diagnosis to 
transplant on D100M, TRM, RI, LFS, and SURV. An addi­
tional trend analysis for relapse showed a significant linear 
decrease of relapse with grade of aGVHD (P <  .05). So 
each grade higher for aGVHD is associated with a further 
reduction in risk of relapse.
In addition to the detailed 5-grade analysis, a series of 
two group settings for aGVHD absent or present were com­
pared in Table 4. In both group settings the low grades 
were significantly different from the high grades; the only 
exception being one analysis of the relapse incidence (grade
Table 3. Relative Risk of aGVHD Score on Outcome for Patients 
With CML (n = 1,294) After Allogeneic BMT in First Chronic Phase
Grade Relative Risk 95% Confidence
Endpoint aGVHD (RR) Interval for RR P
D100M 1 0.71 0.47-1.08 .11
II 1.07 0.71-1.64 .73
III 2.90 1.79-4.7 <.001
IV 11.2 6.89-18.21 <.001
TRM 1 1.17 0.86-1.61 .31
II 2.05 1.52-2.76 <.001
III 3.95 2.84-5.50 <.001
IV 8.47 6.23-11.5 <.001
RI 1 0.96 0.70-1.30 .77
II 0.83 0.57-1.23 .35
III 0.74 0.35-1.55 .41
IV 0.31 0.07-1.31 .11
LFS 1 0.99 0.64-1.23 .91
II 0.72 0.58-0.91 .004
III 0.42 0.32-0.56 <.001
IV 0.19 0.15-0.25 <.001
SURV 1 1.01 0.78-1.32 .91
II 0.65 0.50-0.83 <.001
III 0.35 0.26-0.47 <.001
IV 0.16 0.12-0.21 <.001
Relative risks are with respect to grade 0 of aGVHD and with adjust­
ments for age, sex match, T-cell depletion, donor source, year of BMT, 
and interval from diagnosis to transplant
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Table 4. Relative Risk on Outcome in Several Two-Group Settings by the statistical analysis when grade I  is compared ill a Cox
With Adjustments for Age, Sex Match, T-Cell Depletion,
and Donor Source






Interval for RREndpoint Ref. Versus Other P
D100M 0 v l-IV 1.64 1.21-2.24 .001
0-I ll-IV 2.97 2.24-3.96 <.001
0-II w' III + IV 6.22 4.50-8.60 <.001
I v 0 + ll-IV 2.45 1.70-3.53 A # o o
TRM 0 \/|-IV 2.18 1.67-2.84 <,001
0-I v ll-IV 4.08 3.16-5.27 <,001
O-ll v III + IV 9.30 6.48-13.35 <,001
I 0 -I- ll-IV 2.32 1.74-3.11 <,001
Rl 0 v l-IV 0.67 0.49-0.92 ,01
0-I y  ll-IV 0.48 0.33-0.69 A 9 o o
O-ll y lll-IV 0.22 0.11-0.43 <.001
I V 0 H* ll-IV 0.77 0.55-1.08 .12
LFS 0 y l-IV 0.61 0.48-0.79 <.001
0-I y ll-IV 0.35 0.27-0.46 <.001
O-ll v III + IV 0.16 0.11-0.23 <.001
I v  0 + ll-IV 0.53 0.41-0.70 <•001
Relative risk of reference group (Ref) = 1.
I v others). So each subdivision in “ low” and “ high” grades 
is able to differentiate for each endpoint. But closer scrutiny 
shows that grades III and IY are most responsible for this 
effect; the more advanced, the more significant is the relative 
risk (RR). The distinct effects of 0, I, and II aGVHD are 
lost.
This finding prompted us to analyze outcome for patients 
with grades 0, I, and II only. The differences between the 
grades 0, I, and II are small and not significant when each 
grade is compared with the others. However, the trend analy­
sis shows significant linear decrease in relapse incidence 
with each grade of aGVHD (P <  .05). The lower relapse 
rate in grade II is offset by a higher TRM compared to grades 
0 and I. Because TRM between grades I and 0 is similar, 
the net result is a survival advantage for grade I. This biologi­
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Fig 2. Probability of LFS according to Kaplan and Meier depending 
on grade of aGVHD.
DISCUSSION
Twenty years ago, Glucksberg et al8 described the clinical 
manifestations of GVTID in human recipients of HLA-identi- 
cal sibling donor marrow. With this analysis of 61 patients 
the classification of aGVHD was based on clinical manifesta­
tions o f the main organs involved, skin, gastrointestinal tract, 
and liver into a scoring system (-1- to +  + + + )  for each organ 
and an overall grade from I to IV. It is interesting to observe 
that the GVHD incidence reported in his analysis (grade 0, 
30%; I, 11%; II, 25%; III, 18%; IV, 16%), although showing 
a similar trend as our evaluation has shifted to less severe 
GVHD (grade 0, 36%; I, 26%; II, 20%; III, 9%.; IV 
P  = .005) compared with Glucksberg et al’s results, probably 
because of improved GVHD prophylaxis and despite a pro­
portion of BMT (10%) performed with nonidentical related 
and unrelated donors. The predictive value of the aGVHD 
grading for mortality rate already described by Glucksberg
et al8 (grade 0 GVHD, 44%; I, 43%; II, 80%; III, 91%; IV,
90%) with best survival for patients with grade I has re­
mained, but the outcome has improved since except for grade 
IV. This finding can be explained by the fact that grade IV 
is mainly assigned retrospectively to patients who die with 
aGVHD within 100 days (grade 0 GVHD, 39%; I, 32%; II, 
45%; III, 64%; IV, 93%).
The findings on incidence and severity in this study con­
firmed earlier reports, but also showed unexpected findings. 
aGVHD is clearly more frequent and more severe in patients 
receiving nonidentical family or unrelated transplants. As 
expected, the same holds true for patients given non— T- 
cell-depleted transplants. In contrast, we observed the same 
incidence and severity of aGVHD in patients younger than 
20 years compared with older than 20 years. The effect of 
age on GVHD described previously',,l° might be lost in the 
present patient population because only a few younger pa­
tients (12% < 2 0  years) are reported. Interestingly, 
similar incidence and severity of GVHD in younger patients, 
TRM was lower than in older patients. This means that 
younger patients tolerate aGVHD and its treatment belter. A 
similar observation concerns male patients receiving female 
donor marrow. They have the same incidence and severity 
of aG VHD as other patients, but, as previously reported, a 
higher TRM.11 Factors other than aGVHD must account for 
the higher TRM.
With the introduction of new GVHD prevention methods, 
such as cyclosporin and T-cell depletion and the recognition
Table 5. Relative Risk of aGVHD Grade I v Grade 0 +
Endpoint Relativo Risk (RR)
95% Confidence
Interval for RR P
D100M 0.69 0.47-1.00 .05
TRM 0.71 0.52-0.96 .02
Rl 1.03 0.72-1.49 .86
LFS 1.3 1.00-1.73 .05
Analysis restricted to 1,061 patients with grade 0, I, or II.
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of additional clinical signs of aGVHD, such as nausea, vom- confirm the relevance o f  a G V H D  grading not only for SURV
iting, and upper gastrointestinal tract symptoms, the value and LFS, but also for D 1 0 0 M , TRM , and RI. GVHD has a
of the Seattle criteria has been debated. This uneasiness has different impact on D 100M  th a n  on TRM. Grade II GVHD
been further supported by a study conducted by the IBMTR does not influence D100M , a lth o u g h  it clearly does influence
in which BMT teams were asked to grade a simulated patient TRM. This difference m ight b e  explained by the possible
according to their criteria.12 There was significant dis- complications associated w ith  aGVI-ID, such as chronic
cordance for individual patients, but overall good agreement GVHD, infections, and in terstitia l pneumonia resulting in
for the categories absent, moderate, or severe aGVHD. In the death of the patients after d a y  l()().iK For RI there is no
many reports aGVHD is therefore only presented as absent, cut off point. There is a con tin u ou s decrease of RI with
moderate, or severe or as grade less than II versus s= II. No increasing GVHD, suggesting that GVL parallels GVHD in
studies have assessed the predictive value of the detailed its intensity. As a co n seq u en ce  of the divergent effect of
TRM and RI, LFS and S U R V  appear superior for patients 
with grade I aGVHD. This p o te n tia l beneficial effect of gradeWe
topatients transplanted for CML and reported to the EBMT I aGVHD on LFS ju stifies  
was analyzed, updated, and verified by participating teams. aGVHD in autologous B M T . O verall, our findings show that
the Seattle GVHD grading r e m a in s  valid after more than 20We
had any impact on outcome. If so, we wanted to know years after its first description and that the simplification to 
whether an identical or different impact on the five endpoints less than II and a l l  is not ju stified , because patients with 
measured was observed.
In the late 1970s, GVHD was reported to contribute to 
improved survival after allogeneic BMT.13 Survival among
different GVHD grades have different outcomes. Depending 
on the endpoint analyzed, grad in g  should be reported in 
detail for data comparison.
163 patients alive without disease 150 days after BMT for 
acute leukemia in remission or in relapse was best in patients 
with GVHD (acute and chronic) in comparison to patients 
without GVHD. More recently, the influence of acute and 
chronic GVHD on relapse and survival was examined in a 
larger group of patients (n =  1,202).2 Sullivan et al2 were 
able to show that acute and chronic GVHD were associated 
with a durable antileukemic effect and improved survival in
A P P E N D I X
List of participating t e a m s  (no. of patients reported): 
RPMS Hammersmith H o sp ita l,  London, J.M. Goldman 
(158); Ospedale San M artino, Genova, A. Bacigalupo (109); 
Huddinge Hospital, H u d d in g e , G. Gahrton (64); Hospital 
Clinic, Barcelona, E. Carreras (62); Hospital San Orsola, 
Bologna, G. Bandini (59); K antonsspital, Basel, A. Gratwohl
patients transplanted in advanced stage of ALL and CML. (50); University Hospital, N ijm e g e n , T. de Witte (47); Uni- 
However, among patients with ALL in first remission or versità degli Studi la S ap ien za , Rom e, W. Arcese (41); Hôpi-
CML in chronic phase, mild to severe GVHD (grades II-IV) tal Henri Mondor, Créteil, J. V ern an t (38); Royal Free
had an adverse effect on survival and they failed to observe tal, Hampstead, London, H .G . Prentice (34); Ospedale di
a positive influence on relapse. A few years later, this finding 
was supported in more detail by Nash et al,9 showing a 
negative effect of the different aGVHD grading (O-I, II, and 
III-IV) on survival.9 In our analysis, in which each GVHD
Careggi, Firenze, P. R o ss i-F e r in i (29); University Hospital, 
Leiden, R. Willemze (28); U n iversity  Hospital, Leuven, M. 
Boogaerts (26); Ospedale C iv i le ,  Pescara, G. Torlontano 
(26); Medicai School o f  H a n n o v er , Hannover, H. Link (24);
grade has been analyzed separately in a large population of Med Klinik III, Klinikum Grosshadern, München, H. Kolb
patients with a single disease transplanted at the same stage (24); Cliniques U niversitaires S t Luc, Brussels, A. Ferrant
of the disease, we have confirmed the negative influence of (23); Hospital “ Marques d e  V aldecilla ,” Santander, A. lri-
GVI-ID grades II, III, and IV on survival. For the first time 0ndo (22); Hôpital A. M ic h a llo n , Grenoble, D. Hollard (22);
in patients with CML in chronic phase we can now also University of Helsinki, H e ls in k i,  T. Ruutu (22); Hôpital Saint
document a positive effect o f grade I GVHD. This finding Louis, Paris, E. Gluckman (2 1  ); Universität Ulm, Ulm, R.
might be explained by the decreased RI and unchanged TRM Arnold (19); Royal M arsd en  Hospital, Sutton, Surrey, R.
in comparison to patients without GVHD. Decreased RI Powles (16); Inst Paoli I. C a l m ettes, Marseille, D. Maranin-
might be caused by the graft-versus-leukemia (GVL) effect 
of GVI-ID.14'17 The findings of minor histocompatibility anti-
chi (16); Daniel Den H o ed  Cancer Center, Rotterdam, .1. 
Cornelissen (16); R ik sh osp ita le t, Oslo, S. Evensen (15);
gen-specific cytotoxic T cells in vitro that can recognize London Clinic LOBG, L o n d o n , D. Gueret-Wardle (15);
leukemic cells lends support to our clinical findings. For Heinrich-Heine-Universität, Düsseldorf, V. Runde (14); Inst.
aGVHD grades higher than I, the decreased RI is offset by Scienze Mediche, M ilano, G . Lambertenghi-DeliIiers (12);
the increased TRM resulting in overall lower LFS. Vice King Faisal Specialist H o sp ita l, Riyadh, P. Ernst (12); Uni-
versa, the lower incidence and severity of aGVHD in patients versity College Hospital, L ondon, A.H. Goldstone (11);
with T-cell depletion is offset by the loss of GVL and in- Klinikum Rudolf V irchow , B erlin , W. Siegert (11); Hôpital
creased relapse rate. Jean Minjoz, Besançon, J. C a h n  (10); University Hospital,
Results of the present analysis therefore validate the initial Utrecht, L. Verdonck (10); R oya l Infirmary, Edinburgh, A.
Seattle classification and their predictive value. It is comfort- Parker (9); Hospital Reina S o f ia ,  Cordoba, A. Torres Gomez
ing to see that incidence and severity o f GVHD have de- (9); Hôpital du Haut L e v è q u e , Pessae, j. Reifïers (9); Rigs-
clined since the initial report of Glucksberg et al8 and that hospitalet, Copenhagen, N .  Jacobsen (8); Christian-Al-
survival for any grade has substantially improved. The data brechts-Universitât, Kiel, N .  Schmitz (8); lbn-i-sina Hospi-
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